Learn About Acute Megakaryoblastic Leukemia

View Main Condition: Leukemia

What is the definition of Acute Megakaryoblastic Leukemia?
A rare acute myeloid leukemia that occurs predominantly in childhood and particularly in children with Down syndrome (DS-AMKL). Nonspecific symptoms may be irritability, weakness, and dizziness while specific symptoms include pallor, fever, mucocutaneous bleeding, hepatosplenomegaly, neurological manifestations and rarely lymphadenopathy. Acute panmyelosis with myelofibrosis may also be associated with AMKL. In contrast to DS-AMKL (around 80 % survival), non-DS-AMKL is an AML subgroup associated with poor prognosis.
Save information for later
Sign Up
What are the alternative names for Acute Megakaryoblastic Leukemia?
  • Acute megakaryoblastic leukemia
  • AMKL
  • AML M7
  • Acute megakaryocytic leukemia
  • Acute myeloblastic leukemia type 7
  • Acute myeloid leukemia M7
Who are the top Acute Megakaryoblastic Leukemia Local Doctors?
DR
Dirk N. Reinhardt
Elite
Highly rated in
19
conditions

Universtitätsklinikum Essen AöR

Essen, DE 

Dirk Reinhardt practices in Essen, Germany. Reinhardt is rated as an Elite expert by MediFind in the treatment of Acute Megakaryoblastic Leukemia. He is also highly rated in 19 other conditions, according to our data. His top areas of expertise are Acute Megakaryoblastic Leukemia, Childhood Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML), Leukemia, and Bone Marrow Transplant.

TG
Dr. Tanja A. Gruber
Pediatric Hematology Oncology | Pediatrics
Elite
Highly rated in
6
conditions
Pediatric Hematology Oncology
Pediatrics

Stanford Childrens Health

725 Welch Rd, 
Palo Alto, CA 

Tanja Gruber is a Pediatric Hematologist Oncology specialist and a Pediatrics expert in Palo Alto, California. Gruber has been practicing medicine for over 20 years and is rated as an Elite expert by MediFind in the treatment of Acute Megakaryoblastic Leukemia. She is also highly rated in 6 other conditions, according to our data. Her top areas of expertise are Acute Megakaryoblastic Leukemia, Childhood Acute Myeloid Leukemia, Leukemia, Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplant. Gruber is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn more
SM
Dr. Soheil S. Meshinchi
Pediatric Hematology Oncology | Hematology | Oncology
Elite
Highly rated in
14
conditions
Pediatric Hematology Oncology
Hematology
Oncology

SCCA Wellness Center At South Lake Union

1100 Fairview Ave N, 
Seattle, WA 

Soheil Meshinchi is a Pediatric Hematologist Oncology specialist and a Hematologist in Seattle, Washington. Meshinchi has been practicing medicine for over 29 years and is rated as an Elite expert by MediFind in the treatment of Acute Megakaryoblastic Leukemia. He is also highly rated in 14 other conditions, according to our data. His top areas of expertise are Childhood Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML), Acute Megakaryoblastic Leukemia, Leukemia, and Bone Marrow Transplant. Meshinchi is currently accepting new patients.

View All Doctors
What are the latest Acute Megakaryoblastic Leukemia Clinical Trials?
Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells to Facilitate the Engraftment of a Single CCR5Δ32 Homozygous or Heterozygous Cord Blood Unit in Patients With HIV and Hematological Malignancies
Who is this study for: Patients with Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
Enrollment Status: Recruiting
Publish Date: November 07, 2022
Intervention Type: Drug, Radiation, Procedure, Biological
Study Drugs: FludarabineCyclophosphamideThiotepa
Study Phase: Phase 2

Summary: This phase II trial studies the side effects of a cord blood transplant using dilanubicel and to see how well it works in treating patients with human immunodeficiency virus (HIV) positive hematologic (blood) cancers. After a cord blood transplant, the immune cells, including white blood cells, can take a while to recover, putting the patient at increased risk of infection. Dilanubicel consists of...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase II Trial of Azacitidine (NSC-102816) Plus Gemtuzumab Ozogamicin (NSC-720568) as Induction and Post-Remission Therapy in Patients of Age 60 and Older With Previously Untreated Non-M3 Acute Myeloid Leukemia
Who is this study for: Adult patients with Acute Myeloid Leukemia
Enrollment Status: Active, not recruiting
Publish Date: October 18, 2022
Intervention Type: Drug
Study Drugs: AzacitidineGemtuzumab
Study Phase: Phase 2

Summary: This phase II trial is studying the side effects of giving azacitidine together with gemtuzumab ozogamicin to see how well it works in treating older patients with previously untreated acute myeloid leukemia. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Azacitidine may also...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center

What are the Latest Advances for Acute Megakaryoblastic Leukemia?
Hematological neoplasia associated with primary mediastinal germ-cell tumor treated with hematopoietic stem cell transplantation.
Condition: Hematological Neoplasia Associated with Primary Mediastinal Germ-Cell Tumor
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Treatment Used: Hematopoietic Stem Cell Transplantation
Number of Patients: 1
Published: November 04, 2021
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Journal: International journal of molecular sciences
Published: July 02, 2021
Tired of the same old research?
Check Latest Advances
Clinical features and prognosis of pediatric acute megakaryocytic leukemia.
Journal: Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
Published: June 16, 2021
View All Latest Advances